With ICIs, the effect of mutations changes with cancer types
“Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed”: starting from this premise, a group of researchers of the Memorial Sloan Kettering Cancer Center in New York led [more]